John Kocoras

John Kocoras

McDermott Will & Emery

Contact  |  View Bio  |  RSS

Latest Publications

Share:

Focus on China Compliance - Fall 2014

In This Issue: - Between a Rock and a Hard Place: Navigating Disclosures to U.S. Regulators Within the Framework of China’s State Secrets Law - Internal Investigations in China: Collecting and Reviewing Digital...more

11/20/2014 - China Disclosure Requirements Evidence FCPA Internal Controls Internal Investigations SEC State Secrets

HRSA Withdraws 340B Program Proposed Rule

On November 14, 2014, the U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA) withdrew a proposed rule that would have provided guidance on a variety of topics related to the...more

11/20/2014 - HHS HRSA Prescription Drugs Section 340B

Illinois Supreme Court Strikes Down State Eavesdropping Statute

The Illinois Supreme Court recently declared unconstitutional a state law criminalizing the recording of conversations without the consent of all parties. However, significant risks remain for companies and individuals in...more

4/2/2014 - Audio Recording Eavesdropping Surveillance

China Compliance Update: Commercial Bribery Risks Remain Very Real in China

The enactment of new legislation, as well as new and continuing investigations, demonstrates that Chinese regulators have not slowed down their efforts to ferret out corruption in the pharmaceutical sector and related...more

2/13/2014 - Bribery China Compliance Foreign Official White Collar Crimes

China’s Campaign Against Bribery and Corruption Takes a New Turn: A Focus on Information Gathering

Recently, the co-founders of a firm primarily engaged in investigation-related services were arrested in Shanghai. The arrest indicates protected information laws are being rigorously enforced in China, and could signal a...more

10/1/2013 - Bribery China Compliance Corruption Criminal Prosecution Data Collection Data Protection Personally Identifiable Information

Observations on a Milestone Bribery Investigation and Increased Scrutiny of Foreign Companies in China

The Chinese government’s recent crackdown on alleged bribery and corruption of local officials by multinational pharmaceutical companies could signal a broad trend toward elevated scrutiny of all foreign corporations...more

7/30/2013 - Bribery China Compliance Corruption Due Diligence FCPA Foreign Corporations GlaxoSmithKline UK Bribery Act

6 Results
|
View per page
Page: of 1